| Sheila Eichenseer, | |
|
W129n7055 Northfield Dr, Community Memorial Medical Commons, Menomonee Falls, WI 53051-0538 | |
| (262) 253-2510 | |
| (262) 253-3399 |
| Full Name | Sheila Eichenseer |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 17 Years |
| Location | W129n7055 Northfield Dr, Menomonee Falls, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831345057 | NPI | - | NPPES |
| 1831345057 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 125.053039 (Illinois) | Secondary |
| 2084N0400X | Psychiatry & Neurology - Neurology | 61096 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc | 3678760063 | 1040 |
News Archive
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Age alone should not determine surgical risk in a person age 80 or over, according to expert commentary from Mark Katlic, M.D., director of Thoracic Surgery at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. Dr. Katlic's commentary complements a McGill University Health Science Center trend study, appearing in this week's edition of the Canadian Medical Association Journal (CMAJ). The study finds an increase in coronary artery bypass grafts (CABGs) and percutaneous coronary interventions (PCIs) with better results in people previously believed to be too old for these procedures.
A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.
Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Age alone should not determine surgical risk in a person age 80 or over, according to expert commentary from Mark Katlic, M.D., director of Thoracic Surgery at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. Dr. Katlic's commentary complements a McGill University Health Science Center trend study, appearing in this week's edition of the Canadian Medical Association Journal (CMAJ). The study finds an increase in coronary artery bypass grafts (CABGs) and percutaneous coronary interventions (PCIs) with better results in people previously believed to be too old for these procedures.
A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.
Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Age alone should not determine surgical risk in a person age 80 or over, according to expert commentary from Mark Katlic, M.D., director of Thoracic Surgery at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. Dr. Katlic's commentary complements a McGill University Health Science Center trend study, appearing in this week's edition of the Canadian Medical Association Journal (CMAJ). The study finds an increase in coronary artery bypass grafts (CABGs) and percutaneous coronary interventions (PCIs) with better results in people previously believed to be too old for these procedures.
A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.
Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sheila Eichenseer, W129n7055 Northfield Dr, Community Memorial Medical Commons, Menomonee Falls, WI 53051-0538 Ph: (262) 253-2510 | Sheila Eichenseer, W129n7055 Northfield Dr, Community Memorial Medical Commons, Menomonee Falls, WI 53051-0538 Ph: (262) 253-2510 |
News Archive
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Age alone should not determine surgical risk in a person age 80 or over, according to expert commentary from Mark Katlic, M.D., director of Thoracic Surgery at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. Dr. Katlic's commentary complements a McGill University Health Science Center trend study, appearing in this week's edition of the Canadian Medical Association Journal (CMAJ). The study finds an increase in coronary artery bypass grafts (CABGs) and percutaneous coronary interventions (PCIs) with better results in people previously believed to be too old for these procedures.
A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.
Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
Peter Joosse, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: N91w17271 Appleton Ave, Suite 1, Menomonee Falls, WI 53051 Phone: 262-502-3300 | |
Dr. Abedrazik Hashim Eisa, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: W180n8085 Town Hall Rd, Department Of Psychiatry, Menomonee Falls, WI 53051 Phone: 262-257-5100 Fax: 262-257-2570 | |
Sajjad Nasir, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: W129n7055 Northfield Dr, North Hills Health Center, Menomonee Falls, WI 53051 Phone: 262-253-2510 Fax: 262-253-3399 | |
Margaret E. Sweet, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: W180n7950 Town Hall Rd, Menomonee Falls, WI 53051 Phone: 262-255-2500 Fax: 262-250-6010 | |
Todd Boffeli, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: N91w17271 Appleton Ave, Suite 1, Menomonee Falls, WI 53051 Phone: 262-502-3300 | |
Robert Risinger, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: W180n8085 Town Hall Rd, Menomonee Falls, WI 53051 Phone: 262-251-1005 Fax: 262-257-2570 | |
Asad Ullah, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: N84w16889 Menomonee Ave, Menomonee Falls, WI 53051 Phone: 262-251-7500 Fax: 262-250-1854 |